Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity.

Budihardjo II, Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH.

Mol Pharmacol. 2000 Mar;57(3):529-38.

PMID:
10692493
2.

Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent.

Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM.

Biochem Pharmacol. 1999 Sep 15;58(6):1057-66.

PMID:
10509758
3.

6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin.

Budihardjo II, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S, Shah GM, Poirier GG, Reid JM, Ames MM, Kaufmann SH.

Clin Cancer Res. 1998 Jan;4(1):117-30.

4.
5.

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

Adjei AA, Budihardjo II, Rowinsky EK, Kottke TJ, Svingen PA, Buckwalter CA, Grochow LB, Donehower RC, Kaufmann SH.

Clin Cancer Res. 1997 May;3(5):761-70.

6.

Chemotherapy-induced apoptosis.

Mesner PW Jr, Budihardjo II, Kaufmann SH.

Adv Pharmacol. 1997;41:461-99. Review. No abstract available.

PMID:
9204156

Supplemental Content

Loading ...
Support Center